Black Diamond Therapeutics appoints Mark Velleca as CEO; David Epstein steps down

Black Diamond Therapeutics, Inc.

David M. Epstein separated as President and CEO effective Sept 15, 2023; remains on board until 2024 annual meeting.
Mark Velleca, M.D., Ph.D. appointed President and CEO effective Sept 16, 2023; continues as Chairman.
Velleca receives $620K base salary, 55% target bonus, and stock options for 1,000,000 shares.
Samarth Kulkarni appointed Lead Independent Director; Audit/Nominating committees unchanged.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Samarth Kulkarni

Lead Independent Director

BDTX · Black Diamond Therapeutics, Inc.

Effective: 2023-09-16
Filed: September 18, 2023, 7:59 PM ET

The Board appointed Samarth Kulkarni, Ph.D. to serve as the Lead Independent Director of the Board

Departed

David M. Epstein

President and Chief Executive Officer

BDTX · Black Diamond Therapeutics, Inc.

Effective: 2023-09-15
Successor: Mark A. Velleca
Filed: September 18, 2023, 7:59 PM ET

On September 18, 2023, Black Diamond Therapeutics, Inc. (the “Company”) announced that it separated with David M. Epstein, Ph.D. as President and Chief Executive Officer and principal executive officer of the Company, in each case, effective as of September 15, 2023

Appointed

Mark A. Velleca

President and Chief Executive Officer

BDTX · Black Diamond Therapeutics, Inc.

Effective: 2023-09-16
Filed: September 18, 2023, 7:59 PM ET

Effective September 16, 2023, the Board appointed Mark A. Velleca, M.D., Ph.D. as President and Chief Executive Officer and principal executive officer of the Company

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.9

Samarth Kulkarni was appointed as Lead Independent Director at Black Diamond Therapeutics, Inc..

Action: appointed
Role: Lead Independent Director

Exact text from the filing

The Board appointed Samarth Kulkarni, Ph.D. to serve as the Lead Independent Director of the Board

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

David M. Epstein departed as President and Chief Executive Officer at Black Diamond Therapeutics, Inc..

Action: separated
Role: President and Chief Executive Officer

Exact text from the filing

On September 18, 2023, Black Diamond Therapeutics, Inc. (the “Company”) announced that it separated with David M. Epstein, Ph.D. as President and Chief Executive Officer and principal executive officer of the Company, in each case, effective as of September 15, 2023

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Mark A. Velleca was appointed as President and Chief Executive Officer at Black Diamond Therapeutics, Inc..

Action: appointed
Role: President and Chief Executive Officer

Exact text from the filing

Effective September 16, 2023, the Board appointed Mark A. Velleca, M.D., Ph.D. as President and Chief Executive Officer and principal executive officer of the Company

View on SEC.gov

Black Diamond Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-101377

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.